Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary
May 13, 2024
Earnings Call Speaker Segments
Ed Berg
executiveHello everyone, and thank you for being here on the call today. Joining us from Vaxart are Steven Lo, our Chief Executive Officer; Dr. Sean Tucker, our Founder and Chief Scientific Officer; Dr. James Cummings, our Chief Medical Officer; and Phillip Lee, our Chief Financial Officer. I'd like to note before we begin that during this conference call, forward-looking statements may be made by Vaxart. These cover the company's financial results, its financial guidance, future business strategies and operations, and progress in product development and regulatory matters, including statements concerning clinical trials that are underway or planned. The outcomes we actually achieve might end up substantially different from what these forward-looking statements suggest, and that's because of several significant elements — among them the unpredictable nature of clinical development and the regulatory approval pathway, plus additional dangers outlined under the Risk Factors heading in the Form 10-K annual report Vaxart filed most recently, as well as in its other periodic filings with the SEC. Vaxart assumes no duty to revise any forward-looking statements once this call has taken place. At this point I'll hand things over to Steven Lo. Steve?
Steve Lo
executiveThank you, Ed, and I appreciate everyone being here today. During this call, I'll give you a quick overview of who I am, talk about what we've achieved lately, and walk through the exciting value proposition we offer. After that, I'll hand things over to James and Phil, who will go over our recent progress—covering encouraging data from our bivalent norovirus vaccine candidate in lactating mothers, milestones on the horizon, and a financial update. Because this marks my first quarterly results call since becoming Vaxart's CEO, I want to start with a short introduction. Most of my career—more than 25 years—has been in health care, biotech and pharmaceuticals, and for over 12 years I've been a C-level executive at publicly traded biotech companies. Over that time, I've led organizations across all phases of drug development, starting with preclinical work and continuing through product launch and commercialization. In earlier roles, I built hands-on experience creating clinical programs and executing commercial strategies—expertise that will be essential as we move Vaxart's pipeline forward. What attracts me to biotech is the opportunity to find the right health care solutions for society's hardest unsolved challenges. That's the reason I joined Vaxart. In my view, the company has strong science and a committed team of scientific specialists who are centered on providing breakthrough solutions that improve public health around the globe. I feel enormous excitement about leading Vaxart as we move our pipeline of advanced vaccine candidates forward to achieve better public health results. Execution will be one of my main priorities, enabling us to realize Vaxart's potential more quickly, address significant public health challenges, and simultaneously build shareholder value. I'll now offer some comments on how our pipeline is progressing. First, we are very encouraged by the latest favorable data from the Phase I clinical study of our oral pill bivalent norovirus vaccine candidate in mothers who are breastfeeding. According to the study's top-line results, our vaccine was able to produce a meaningful rise in norovirus antibodies present in breast milk. For our vaccine's potential to guard the youngest and most vulnerable population against norovirus, or to make their illness less severe, this counts as a key early signal, given that this virus imposes an enormous economic toll across the United States and other developed nations worldwide. Moving forward, our norovirus program will hold a meeting with the FDA in mid-2024, where we will go over the clinical data gathered so far — namely, our dose-ranging Phase II trial of the bivalent norovirus vaccine candidate, along with our Phase II challenge study covering the G11 component of that same bivalent norovirus vaccine candidate. We think this meeting will help us figure out the regulatory route and what our clinical next steps should be. Also, we're hoping to kick off our Phase IIb trial for COVID-19 as soon as this quarter. The moment we secure additional funding and come to terms with regulators, it's been a privilege to receive an initial contract from BARDA, and we look forward to working with them on Project NextGen as we continue preparing for that trial. In this Phase IIb study, we'll be evaluating our oral pill XBB COVID-19 vaccine candidate against a superior mRNA comparator. We share the federal government's view that improved vaccines are required, and we think these next-generation vaccines will encompass ones that leverage mucosal immunity's strength, such as our novel candidates. We anticipate sharing an update regarding funding and our timeline when developments justify it; we take pride in the expanding collection of data that strengthens our assurance in our distinctive technology, and we keep enhancing that technology. Fresh preclinical data indicates our COVID-19 XBB construct generated a stronger immunogenic response than our earlier constructs did. Given these findings, we are investigating if particular modifications we made to our XBB vaccine candidate could also help other indications within our pipeline. We think Vaxart is ideally situated to capture the chance before us and push forward our oral vaccine platform. The data we have gathered so far are persuasive across respiratory and enteric programs, and we are resolved to keep moving toward our aim of delivering these solutions to the populations that require them, in the United States and around the world. I will now hand the call over to James so he can go over the recent progress of our norovirus and COVID-19 programs.
James Cummings
executiveThank you, Steve. We feel good about the strides made across our norovirus and COVID-19 efforts. To begin with norovirus: at the end of last month, we shared favorable top-line results from a Phase I trial testing whether our norovirus vaccine candidate could generate antibodies in the breast milk of nursing mothers. As you may remember, the Bill & Melinda Gates Foundation provided partial funding for this work. Our early review showed that antibodies against norovirus increased by an average of 4.0 fold for the GI.1 strain and 6.0 fold for the GII.4 strain in the breast milk of nursing mothers given our Vaxart vaccine candidate in the high dose cohort. What mattered most here: we saw no significant side effects linked to the shot, and nothing that capped the dose because of toxicity. Those findings matter because they may offer moms a way to protect their kids from this highly transmissible virus, or at least soften its effects. Giving mucosal immunizations to the littlest kids is tough, since their immune systems haven't finished developing, yet our novel approach—passing antibodies passively from mother to baby—could bolster infants' ability to fight off infection. Norovirus represents a very grave illness globally, carrying an economic toll of more than $60 billion annually. It most frequently hits the youngest group—kids below 8 years old—because norovirus generates a huge number of outbreaks compared with other infectious diseases. When it comes to the developing world, death rates are much greater than they are in developed nations, especially where rotavirus vaccination efforts are already in place. Roughly 50,000 children die each year because of norovirus, and that burden falls mostly on developing countries. To give some background, this trial was a Phase I, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Its goal was evaluating how safe, tolerable, and immunogenic an orally-administered bivalent GI.1, GII.4 norovirus vaccine would be in healthy breastfeeding women who were 18 or older. Enrollment totaled 76 participants at 5 South African sites. Participants were assigned by randomization to receive either a high dose, a medium dose, or a placebo. Findings related to safety are still blinded, and they are expected to be released 12 months following enrollment. Additional analysis of the study data is underway, and we anticipate sharing fuller findings, among them additional immunogenicity measurements, through a forthcoming scientific manuscript. As we look forward, per Steve's earlier remarks, our aim is a meeting with the FDA around the middle of 2024 to go over what we have on possible correlates of protection, along with possible upcoming clinical trials—for instance a Phase IIb study to confirm dose and, should it be necessary, a GII.4 challenge study. There's optimism on our side that if the safety data from a Phase IIb trial holds up, we could secure an end of Phase II meeting with the FDA. That meeting would center on what a Phase III pivotal efficacy study for our norovirus vaccine in adults 18 and older should look like and how broad it ought to be. Now, on to our COVID-19 program. Work keeps moving forward as we get ready for a Phase IIb clinical trial of 10,000 subjects, one that tests our oral pill XBB COVID-19 vaccine candidate head-to-head against an improved mRNA vaccine comparator. As some of you might remember, funding for getting that study ready came through a BARDA contract, and it falls under Project NextGen, the federal initiative aimed at boosting how prepared the country is for pandemics and improving our ability to handle the ongoing COVID-19 problem. We've mostly wrapped up getting our manufacturing processes ready ahead of kicking off this trial; our efforts now focus on obtaining further financing and getting on the same page with regulators, and assuming that goes well, our present expectation is that we could start this Phase IIb trial as soon as the second quarter. To give some background, this study is a Phase IIb trial — double-blind, multicenter, randomized, and comparator controlled — that's meant to evaluate how well Vaxart's investigational oral SARS-CoV-2 XBB vaccine tablet stacks up against an approved mRNA booster administered by injection when it comes to relative efficacy, safety, and immunogenicity. The participants are adults who already have been vaccinated against COVID-19. With that, I'll hand things over to our Chief Financial Officer, Phil Lee, for a quick rundown of our financials. Phil?
Phil Eric Lee
executiveI appreciate that, James. Today's press release lays out the specifics of how we performed financially in the first quarter of 2024. Our revenue came to $2.2 million for the first quarter of 2024, versus $0.7 million during the same period in 2023. Most of that first-quarter 2024 revenue stemmed from work we performed or revenue we recognized under the contract Vaxart holds with BARDA, along with noncash royalty revenue generated by Inavir sales in Japan. When the first quarter closed, Vaxart held $36.7 million in cash, cash equivalents and investments. We got no cash payments at all from BARDA in that first quarter, though roughly $1.6 million has come in since the quarter ended. As part of the BARDA contract we currently have, we're working through the remaining deliverables and permitting tied to the remaining $7.67 million, and once we report our second quarter financial results, we'll share an update. Under the plan we have right now, Vaxart expects its current cash to last into late in the fourth quarter of 2024. I want to thank all of you for making time today. At this point, we'll open up the call for your questions.
Madison El-Saadi
analystMadison here, sitting in for Mamtani. I'd like to ask — could you possibly describe what has to be shown in order to secure that extra filing so the Phase IIb BARDA can get underway? And perhaps you could also address how confident you feel about your position when it comes to — getting hold of those funds that are required.
Steve Lo
executiveYes. I appreciate the question; let me address a few points, and then I'll hand things to James for the details. On the confidence question, right? The initial award, totaling $9.27 million, was intended to finance preparation for the study of 10,000 subjects. And just as James and I have both described, we moved that forward. I believe you can actually observe in the financial results that we've had some of that work reimbursed; that's the reason we keep stating that we're ready to launch the trial as early as this quarter. But I'll also pass it to James.
James Cummings
executiveAppreciate that, Steve. Regarding getting the study ready, I believe our team has performed really well in assembling everything needed to evaluate the XBB construct versus a better mRNA comparator vaccine. This trial is substantial. We're talking 10,000 participants, correct? So establishing all of those food groups — that requires the team, and we have a strong one. As for our current position, once we have those specifics, we'll share them with you; however, we've stayed in frequent contact with BARDA regarding the preparations, and when it makes sense, we intend to give an update on funding as well as our timing.
Charles Duncan
analystAlethia here, filling in for Charles. We’ve got another question about the Phase IIb trial of the COVID-19 vaccine. Could you describe the particular endpoints and criteria planned for assessing how well it works and how safe it is compared with the mRNA vaccine? Also, please explain what enrollment in this trial would involve—for instance, the locations patients might be recruited from. And what other difficulties do you expect?
Steve Lo
executiveAbsolutely. I’ll hand that to James, because he’s the one with those specifics.
James Cummings
executiveAbsolutely. Regarding the location where the clinical trial will actually be run, the plan is for it to take place within the United States. When it comes to who will be enrolled, those participants would be healthy people as well as individuals at elevated risk who are older than 18. There's — it matters that we evaluate this vaccine against the comparator mRNA vaccine in a group that stands to benefit the most; so that's the direction we're taking. Could you remind me what the latter portion of your question was, Alethia?
Analyst
analystSo it had to do with likely endpoints and the criteria that you'll apply for this trial.
James Cummings
executiveRight. Safety is the endpoint, as always, correct? And we're quite lucky because our platform, in each article throughout our pipeline portfolio, has been received very favorably, extremely safe, and tolerated well. In addition, we'll examine efficacy, both regarding symptomatic COVID-19 infection versus the comparator vaccine. And we'll be examining the immunological readouts along with mucosal readouts for that vaccine.
Liang Cheng
analystLiang Cheng here, filling in for Roger. From our side, my understanding is that a meeting with the FDA hasn't happened yet. But when it comes to the possible Phase II challenge study, what kinds of things would factor into deciding whether such a study takes place or not? Also, I have a question regarding the potential immunology correlates. Could you remind us whether data analysis is still ongoing? And is there anything new or planned when it comes to the immunogenicity correlates?
Steve Lo
executiveSure. Yes. I'll hand things over to James in a moment. At a high level, as we said regarding our meeting with the FDA, we're still aiming for the middle of this year, and James can go into a bit more detail on that.
James Cummings
executiveAppreciate it, Steve. As we already noted, our plan is to sit down with the FDA around the middle of 2024. At that point, we'll go over the clinical results we've gathered so far, which covers information regarding possible correlates of protection. Our expectation is that this conversation will help us figure out the right regulatory route along with what comes next on the clinical side; and like I said in my brief remarks, a Phase IIb dose confirmation study is one of the possibilities among those steps. A GII.4 challenge study is another, should it be needed. Even so, I want to hear what the agency has to say. Once we've had those talks with the FDA, we'll settle on when any upcoming norovirus trials happen.
Liang Cheng
analystUnderstood, that's clear. Then, on the Phase I data for lactating mothers, I realize the full details are going to come out later. Will there be any measurements relating to the infant?
Steve Lo
executiveJames or Sean, would either of you like to address that?
James Cummings
executiveOkay. So, Liang, what we've got up to now is a portion of the topline results, and we're still carrying out additional analyses. A few of those will examine fecal — how much material is present in the infant species. But once again, that's somewhat further out.
Ed Berg
executiveAll right, thanks. We've got some more questions submitted by investors. So I'll begin with the Phase IIb COVID study, and this one's for James. When it comes to making your COVID vaccine for that Phase IIb trial, do you have sufficient manufacturing capacity?
James Cummings
executiveSure. Thanks for the question. Yes, we have sufficient material that's already been produced.
Ed Berg
executiveAppreciate it. And then, James, my second question concerns COVID — specifically the COVID study. In what way does the autumn COVID-19 booster period influence Vaxart's capacity to obtain mRNA vaccines that would be used within the control arm?
James Cummings
executiveAppreciate that, Ed. Essentially, this trial serves as a head-to-head comparison between two homologous vaccines — meaning both are designed to target the identical viral strain. We already have in hand an XBB mRNA vaccine, which functions as the comparator construct required for this study.
Edward Berg
analystAppreciate that, James. Regarding the 108 study, Sean, this one's for you. Your team put out a press release not long ago about the data from the lactating mothers trial, and in it you referenced figures showing antibody increases. How do those stack up against the rest of what's been published?
Sean Tucker
executiveYeah, that's a really good question. So, research involving women who've given birth and then received vaccines hasn't been all that extensive. The majority of maternal studies have focused on the third trimester rather than the period following delivery. On top of that, there's been a real shortage of — actually, zero norovirus vaccine trials have taken place with mothers who are breastfeeding. That said, based on a handful of studies on immunization in post-partum mothers that we won't find, we feel our findings stack up pretty well. The response we're seeing is comparable to, or even better than, what prior reports have shown.
Ed Berg
executiveAppreciate it. This next one goes to Sean — Sean, this is directed at you — but let's return to the topic of COVID-19 along with the Phase IIb trial. What people want to know is this: in what ways does Vaxart's technology stand apart from those other NextGen COVID vaccines that BARDA has awarded contracts to?
Sean Tucker
executiveOkay, so to start with, when it comes to the Project NextGen awardees, we're the sole oral pill vaccine that has been contracted so far. What we view as the upside here is simply that giving our vaccine is more convenient than administering it via injection or even a nasal spray. And naturally, another plus on our side, which James brought up earlier, is that we possess our own production sites, and the fact that they've been capable of producing vaccine fast gives us an edge in the competitive sense because of that.
Ed Berg
executiveMuch appreciated. This is likewise directed at Sean. And Steve, I believe you may wish to jump in with a few remarks. What we're asking is this: in what manner do you plan to inform physicians and the public about the advantages of your oral vaccines for COVID and norovirus, so that uptake can be accelerated across the United States, the United Kingdom, and more widely — especially in light of everything we've come to understand regarding the deficiencies of the vaccines already available, along with the broader problem of vaccine hesitancy? And naturally, speaking as the lawyer, I'll make clear that we won't. Promotion of our vaccines is not something we'll do prior to their approval. Nevertheless, other avenues exist for getting information across. So Sean, at this point, please go ahead and add...
Sean Tucker
executiveSo, we believe our tablet vaccine is going to perform strongly when it comes to getting past vaccine hesitancy. Actually, we had earlier polling information that was carried out during 2021 and 2022, and what came out of that later data indicates that 8 out of 10 people receiving it would choose a pill over an injection or a nasal spray. Beyond that, we've attended a number of medical conferences and congresses. And we've heard a great deal of favorable reaction to our approach, and we take that as a sign that the medical community understands there could be some pent-up demand for a new technology that's simpler to use. Steve?
Steve Lo
executiveAbsolutely. I appreciate that, Sean. Sean’s downplaying himself a bit. He receives plenty of invitations to present at conferences. In my view, any form of scientific exchange along those lines matters. And as we keep putting out additional data, having the chance to do that is something we value. Like Ed said, we don’t have FDA approval at this point. So we’ll stay with the standard medical and scientific exchanges to ensure that what we’ve got and the data we have reach everyone so they can take it in.
Ed Berg
executiveAppreciate that, Steve. I've got something I want to ask you as well. During your prepared remarks, you brought up improved execution. What's your view on how that could be achieved?
Steve Lo
executiveAbsolutely, and I appreciate you asking that. So, the way I see it, the most important thing is that we, as an organization, need to ensure our priorities are in order — and it makes me very happy to see that we do, since, as you've already witnessed and heard about earlier today, we've discussed the need to deliver on what we agreed to with BARDA so we can get ready for the 10,000 subject trial that's coming up. And that's already been shown by the fact that, as James pointed out, we've achieved significant strides when it comes to manufacturing; we got things ready and are getting things ready for that trial to the degree that you've been given additional specifics about it; so from my perspective, that means keeping up the execution. Alongside that, we need to strike a balance by staying extremely disciplined in all our efforts, while at the same time recognizing that our goal is to be of help to the public at large. So whatever we're able to do that balances that against maintaining solid speed also matters. And that, without a doubt, is the way I think about achieving improved execution.
Ed Berg
executiveThe final question goes to Steve. You've now been in the CEO role for close to 2 months. During that period, what have you come to learn?
Steve Lo
executiveAppreciate the question. Let me begin by saying how happy I am to be part of this. What I've come to discover and understand is that the science we have going on at Vaxart is extremely promising. That's one of the biggest reasons I was drawn to this place. And second, after spending 2 months here, having the opportunity to collaborate closely with the staff, our researchers, everyone, I can tell you that our team cares deeply about the work we do and the mission we share. And when you put that promising science together with the committed people at Vaxart, our focus is squarely on pushing our vaccine candidates ahead and getting them out to the world as quickly as possible, with the approvals we require and the trials we need to run and carry out. But our emphasis is firmly on execution and on creating value for our stakeholders.
Ed Berg
executiveAppreciate that, Steve. And thanks to all of you for joining us. I'll hand things back to our operator now so we can wrap up the call.
Operator
operatorAppreciate it. That brings us to the end of today's call. At this point you're free to hang up, and we hope the rest of your day is great. Thanks for joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.